Recent advances in systemic therapy. When HER2 is not the target: Advances in the treatment of HER2-negative metastatic breast cancer

Breast Cancer Research

Volumn 11, Issue 4, 2009, Pages

  Miles, David W ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AXITINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EPOTHILONE B; ERIBULIN; ETHINYLESTRADIOL; ETOPOSIDE; EXEMESTANE; FLUOROURACIL; FLUOXYMESTERONE; GEMCITABINE; IXABEPILONE; LAROTAXEL; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; SORAFENIB; TAMOXIFEN; TOREMIFENE; TRABECTEDIN; UNINDEXED DRUG; VINBLASTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOTOXIN; DRUG CARRIER; DRUG DERIVATIVE; EPOTHILONE DERIVATIVE; ESTRADIOL; FULVESTRANT; HER2 PROTEIN, HUMAN; MAMMALIAN TARGET OF RAPAMYCIN; NANOPARTICLE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TUMOR PROTEIN;

ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; METASTASIS; NEUTROPENIA; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN EXPRESSION; PROTEIN TARGETING; RASH; REVIEW; SENSORY NEUROPATHY; STOMATITIS; SYSTEMIC THERAPY; ADENOCARCINOMA; ARTICLE; BREAST TUMOR; CHEMISTRY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYTOTOXINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; ESTRADIOL; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NANOPARTICLES; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; SALVAGE THERAPY;

EID: 77449160477     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2237     Document Type: Review

References (74)

1. Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007, 18:215-225. 10.1093/annonc/mdl155, 16831851.
2. National Comprehensive Cancer Network NCCN guidelines 2008. National Comprehensive Cancer Network., http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
3. Wolmark N, Dunn BK. The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann N Y Acad Sci 2001, 949:99-108.
4. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18:3758-3767.
5. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001, 19:2596-2606.
6. Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, Cufer T, Roozendaal K, Nooij M, Mattiacci M-R. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts): a randomized phase III trial of the EORTC Breast Group [abstract 515]. J Clin Oncol 2004, 22:6s.
7. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North Ameriscan trial. J Clin Oncol 2002, 20:3386-3395. 10.1200/JCO.2002.10.058, 12177098.
8. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004, 22:1605-1613. 10.1200/JCO.2004.02.112, 15117982.
9. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 58566, 11553815, 10.1073/pnas.191367098.
10. Rakha EA, Tan DS, Foulkes WD, Ellis IO, Tutt A, Nielsen TO, Reis-Filho JS. Are triple-negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res 2007, 9:404. 2246182, 18279542, 10.1186/bcr1827.
11. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer?. Breast Cancer 2008, 15:303-308. 10.1007/s12282-008-0042-3, 18369692.
12. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045, 17671126.
13. Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Schütt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S, . West German Study Group Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 2008, 19:861-870. 10.1093/annonc/mdm551, 18174609, West German Study Group.
14. Chia JW, Ang P, See H, Wong Z, Soh L, Yap Y, Wong N. Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy [abstract 1086]. J Clin Oncol 2007, 25:53s.
15. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008, 19:1847-1852. 10.1093/annonc/mdn395, 18567607.
16. James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 2007, 12:142-150. 10.1634/theoncologist.12-2-142, 17296808.
17. Garber K. Improved paclitaxel formulation hints at new chemotherapy approach. J Natl Cancer Inst 2004, 96:90-91.
18. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803. 10.1200/JCO.2005.04.937, 16172456.
19. Link JS, Waisman JR, Nguyen B, Jacobs CI. Bevacizumab and albumin-bound paclitaxel in metastatic breast cancer [abstract 1101]. J Clin Oncol 2007, 25:57s.
20. Conlin AK, Seidman AD, Moynahan ME, Traina TA, Mace JR, Meiri E, Bach A, Edwards C, Hudis CA. Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound pacli-taxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: an initial interim safety report [abstract 1104]. J Clin Oncol 2007, 25:58s.
21. Gluck S, Lobo C, Hurley J, Lopes G, Reis I, Seo P, Silva O, Slingerland J, Welsh C, Tukia K. Interim results of a phase II study of nabpaclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer (MBC) [abstract 152P]. Ann Oncol 2008, 19:viii68.
22. Dieras V, Limentani S, Romieu G, Tubiana-Hulin M, Lortholary A, Kaufman P, Girre V, Besenval M, Valero V. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol 2008, 19:1255-1260. 10.1093/annonc/mdn060, 18381372.
23. Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res 2003, 63:6026-6031.
24. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001, 7:1429-1437.
25. Buzdar AU. Clinical experience with epothilones in patients with breast cancer. Clin Breast Cancer 2008, 8(suppl 2):S71-S78. 10.3816/CBC.2008.s.003, 18637402.
26. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007, 25:5210-5217. 10.1200/JCO.2007.12.6557, 17968020.
27. Hortobagyi GN, Perez E, Vrdoljak E, Medina C, Xu B, Conte P, Roche H, Peck R, Poulart V, Sparano JA. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials [abstract 186]. ASCO Breast Cancer Symposium; 5 to 7 September 2008; Washington. DC 2008, Alexandria, VA: American Society of Clinical Oncology., http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=58&abstractID=40389
28. Vahdat L, Bunnell C, Schwartzberg L, Gralow J, Poulart V, Klimovsky J, Peck R, Thomas E. Ixabepilone is effective in combination with capecitabine in ER, PR, HER-2 negative (triple negative) patients (PTS) resistant to taxanes and anthracyclines: final results from a breast cancer exploratory program. Ann Oncol 2006, 17:74.
29. Conlin AK, D'Andrea G, Hudis CA, Robson ME, Drullinsky P, Theodoulou M, Lis E, Kang TY, Peereboom DM, Seidman AD. Phase II trial of patupilone in patients with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT) [abstract 1086]. J Clin Oncol 2008, 26:62s.
30. Fumoleau P, Campone M, Vorobiof D, Casado M, Ruff P, Khoo Kei S, Cortes-Funes H, Khalfallah S, Caroff I, Colin C. Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracyclinetaxane failure [abstract 542]. J Clin Oncol 2004, 22:13s.
31. Fumoleau P, Cortes-Funes H, Chan S, Taleb A, Campone M, Pouget JC, Leclerc GF. Phase II study of i.v. vinflunine (VFL) as third-line treatment of metastatic breast carcinoma after failure of anthracycline-/taxane-based chemotherapy [abstract 6070]. Breast Cancer Res Treat 2006, 100:S279.
32. Cortes JA, Campone M, Twelves C, Vahdat LT, Blum JL, Rivera RR, Shuster DE, Wanders J, Fang F, Allison MK. Eribulin mesylate (E7389) in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane: phase II neuropathy data [abstract 157P]. Ann Oncol 2008, 19:viii70.
33. Vahdat LT, Twelves C, Allison MK, Cortes JA, Campone M, Shuster DE, Wanders J, Fang F, Urnani RC, Lum JL. Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane and capecitabine therapy [abstract 1084]. J Clin Oncol 2008, 26:62s.
34. Blum JL, Pruitt BT, Fabian CJ, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Vahdat LT. Phase II study of eribulin mesylate (E7389) in patients with heavily pretreated advanced breast cancer [abstract 223]. 2007 Breast Cancer Symposium; 7 to 8 September 2007; San Francisco, CA 2007, Alexandria, VA: American Society of Clinical Oncology., http://www. asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=52&abstractID=40408
35. Martinez N, Sanchez-Beato M, Carnero A, Moneo V, Tercero JC, Fernandez I, Navarrete M, Jimeno J, Piris MA. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemonaive patients. Mol Cancer Ther 2005, 4:814-823. 10.1158/1535-7163.MCT-04-0316, 15897246.
36. Zelek L, Yovine A, Brain E, Turpin F, Taamma A, Riofrio M, Spielmann M, Jimeno J, Misset JL. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006, 94:1610-1614. 10.1038/sj.bjc.6603142, 16736024.
37. Klencke B, Bhattacharya S, Samant M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Davidson NE, Miller K. Independent review of E2100 validates progression-free survival (PFS) improvement with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC) [abstract 1036]. J Clin Oncol 2008, 26:50s.
38. Miles DW, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, Tomczak P, Taran T, Harbeck N, Steger GG. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstract LBA1011]. J Clin Oncol 2008, 26:1008s.
39. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676. 10.1056/NEJMoa072113, 18160686.
40. Miller KD, Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Pegram MD, Eisenberg PD, Collier M, Adams BJ, Baum CM. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) [abstract]. J Clin Oncol 2005, 23(suppl):563.
41. Bianchi G, Loibl S, Zamagni C, Ardizzoni A, Raab G, Siena S, Wolf C, Westermeier T, Bergamin L, Gianni L. A phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer [abstract 276]. Eur J Cancer Suppl 2005, 3:78.
42. Rugo HS, Stopeck A, Joy A, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Soulieres D. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC) [abstract 1003]. J Clin Oncol 2007, 25:32s.
43. Boer K, Lang I, Llombart-Cussac A, Andreasson I, Vivanco GL, Sanders N, Pover GM, Murray E. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized phase II study [abstract 6081]. Breast Cancer Res Treat 2007, 106:S274.
44. Miller KD, Trigo JM, Stone A, Wheeler C, Barge A, Sledge GW, Baselga J. A phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyosine kinase inhibitor, in patients with previously treated metastatic breast cancer [abstract 6060]. Breast Cancer Res Treat 2004, 88(suppl):240. (plus poster)..
45. Kaufman PA, Broadwater G, Lezon-Geyda K, Dressler LG, Berry D, Friedman P, Winer EP, Hudis C, Ellis MJ, Seidman AD, Harris LN. CALGB 150002: Correlation of HER2 and chromosome 17 (ch 17) copy number with trastuzumab (T) efficacy in CALGB9840, paclitaxel (P) with or without T in HER2+ and HER2-metastatic breast cancer [abstract 1009]. J Clin Oncol 2007, 25:34s.
46. Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, Paridaens R, De Wolf-Peeters C. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 2008, 26:4869-4874. 10.1200/JCO.2007.13.4296, 18794552.
47. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
48. Railo MJ, Smitten KV, Pekonen F. The prognostic value of epidermal growth factor receptor (EGFR) in breast cancer patients. Results of a follow-up study on 149 patients. Acta Oncol 1994, 33:13-17. 10.3109/02841869409098368, 8142117.
49. Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol 2005, 16:538-548. 10.1093/annonc/mdi129, 15746148.
50. di Leo A, Gomez H, Aziz Z, Zvirbule Z, Arbushites M, Oliva CR, Koehler M, Williams LS, Dering J, Finn RS. Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients [abstract 1011]. J Clin Oncol 2007, 25:34s.
51. Winer E, Cobleigh M, Dickler M, Miller K, Fehrenbacher L, Jones C, Justice R. Phase II multicenter study to evaluate the efficacy and safety of TarcevaTM (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer [abstract 445]. Breast Cancer Res Treat 2002, 76:S115.
52. Rugo HS, Dickler MN, Scott JH, Moore DH, Melisko M, Yeh BM, Caravelli J, Brogi E, Hudis C, Park JW. Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation [abstract 525]. J Clin Oncol 2005, 23:10s.
53. Graham DL, Hillman DW, Hobday TJ, Rousey SR, Nair SG, Soori GS, Sabagh TM, Perez EA. N0234:Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC) [abstract 644]. J Clin Oncol 2005, 23:39s.
54. Carey LA, Rugo HS, Marcom PK, Irvin W, Ferraro M, Burrows E, He X, Perou CM, Winer EP. EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer [abstract 1009]. J Clin Oncol 2008, 26:43s.
55. von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U, Lück HJ, Kettner E, Hilfrich J, Eiermann W, Torode J, Schneeweiss A. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 2005, 89:165-172. 10.1007/s10549-004-1720-2, 15692759.
56. Engebraaten O, Natarajan V, Lokkevik E, Naume B, Fodstad O, Aamdal S, Ottestad L. A randomized phase II trial with gefitinib and docetaxel in metastatic breast cancer: an evaluation of the treatment regimen and the factors associated with toxicity. Breast Cancer Res Treat 2006, 100:S69.
57. Tubiana-Hulin M, Spielmann M, Dieras V, Fumoleau P, Delaloge S, Mefti F, Girre V. A multicenter, randomized, double-blind, parallel-group phase II study of gefitinib (IRESSA) or placebo in combination with docetaxel, as first-line treatment in patients with metastatic breast cancer. Breast Cancer Res Treat 2007, 106:S69-S70.
58. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci 2002, 963:104-115.
59. Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004, 90:236-244. 10.1038/sj.bjc.6601504, 14710235.
60. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003, 144:5105-5117. 10.1210/en.2003-0705, 12960029.
61. Dowsett M, Nicholson RI, Pietras RJ. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat 2005, 93(suppl 1):S11-S18. 10.1007/s10549-005-9037-3, 16247595.
62. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pre-treated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005, 23:5314-5322. 10.1200/JCO.2005.66.130, 15955899.
63. Baselga J, Roche H, Fumoleau P, Campone M, Colomer R, Cortes-Funes H, Gil M, Chan S, Boni J, Kong S, Cincotta M, Moore L. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study [abstract 1068]. Breast Cancer Res Treat 2005, 94:S62.
64. Ellard S, Gelmon KA, Chia S, Clemons M, Kennecke H, Norris B, McIntosh L, Seymour L. A randomised phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer [abstract 3513]. J Clin Oncol 2007, 25:141s.
65. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002, 25:511-518. 10.1159/000068621, 12566895.
66. Normanno N, Di MM, De ME, De LA, de MA, Giordano A, Perrone F. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005, 12:721-747. 10.1677/erc.1.00857, 16322319.
67. Ellis CA, Vos MD, Wickline M, Riley C, Vallecorsa T, Telford WG, Zujewskil J, Clark GJ. Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res Treat 2003, 78:59-67. 10.1023/A:1022105511409, 12611458.
68. Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003, 21:2492-2499. 10.1200/JCO.2003.10.064, 12829668.
69. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007, 13:1383-1388. 10.1158/1078-0432.CCR-06-2260, 17332279.
70. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, Ator M, Bihovsky R, Hudkins R, Chatterjee S, Klein-Szanto A, Dionne C, Ruggeri B. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003, 2:371-382.
71. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ. Anti-cancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004, 96:56-67.
72. Nguewa PA, Fuertes MA, Cepeda V, Alonso C, Quevedo C, Soto M, Perez JM. Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med Chem 2006, 2:47-53. 10.2174/157340606775197697, 16787355.
73. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917. 10.1038/nature03443, 15829966.
74. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921. 10.1038/nature03445, 15829967.